Patents on Pharmaceutical Products in Fair International Economic Relations

Abstract Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essen...

Full description

Saved in:
Bibliographic Details
Published in:Perspectives on global development and technology 2019-05, Vol.18 (3), p.249-268
Main Author: Mah, Jai S
Format: Article
Language:English
Subjects:
Developing countries
Drugs
Fairness
GATT
Intellectual property
International economic relations
International economics
International trade
LDCs
Negotiation
Pharmaceuticals
Property rights
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 268
container_issue 3
container_start_page 249
container_title Perspectives on global development and technology
container_volume 18
creator Mah, Jai S
description Abstract Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essential medicines critical to human life and health. The Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) of the WTO includes a few provisions on special and differential treatment (SDT) of developing countries. However, these do not specifically mention pharmaceutical products. Patentability of pharmaceutical products may be analysed in light of fairness. From the viewpoint of distributional fairness, this article derives several policy suggestions for pharmaceutical products in fair international economic relations.
doi_str_mv 10.1163/15691497-12341521
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2269020098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2269020098</sourcerecordid><originalsourceid>FETCH-LOGICAL-b265t-da9c1e91c4f75399f6b949d0bf4b80fc6be658ecc35bf0e1dd8ecc98588798953</originalsourceid><addsrcrecordid>eNp1UMFOAyEQJUYTa_UDvG3ieS2zu1A4mqbVxiY2Rs8EWIg0W6jAHvx7d62NJ08z8968l5mH0C3gewBaz4BQDg2fl1DVDZAKztBkxMoRPD_1BONLdJXSDuMK1xgm6Hkrs_E5FcEX2w8Z91KbPjstu2IbQ9vrgXK-WEkXi7XPJnqZXfADvdTBh73TxavpfrB0jS6s7JK5-a1T9L5avi2eys3L43rxsClVRUkuW8k1GA66sXNSc26p4g1vsbKNYthqqgwlzGhdE2WxgbYdB84IY3POOKmn6O7oe4jhszcpi13oh8O6JKqK8uE1zNmwBcctHUNK0VhxiG4v45cALMbMxCkzccps0MyOGhVd1_3Z_q_4Bi4BbLg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2269020098</pqid></control><display><type>article</type><title>Patents on Pharmaceutical Products in Fair International Economic Relations</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>International Bibliography of the Social Sciences (IBSS)</source><source>Worldwide Political Science Abstracts</source><source>BSC - Ebsco (Business Source Ultimate)</source><source>Alma/SFX Local Collection</source><source>Sociological Abstracts</source><creator>Mah, Jai S</creator><creatorcontrib>Mah, Jai S</creatorcontrib><description>Abstract Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essential medicines critical to human life and health. The Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) of the WTO includes a few provisions on special and differential treatment (SDT) of developing countries. However, these do not specifically mention pharmaceutical products. Patentability of pharmaceutical products may be analysed in light of fairness. From the viewpoint of distributional fairness, this article derives several policy suggestions for pharmaceutical products in fair international economic relations.</description><identifier>ISSN: 1569-1500</identifier><identifier>EISSN: 1569-1497</identifier><identifier>DOI: 10.1163/15691497-12341521</identifier><language>eng</language><publisher>Leiden | Boston: Brill</publisher><subject>Developing countries ; Drugs ; Fairness ; GATT ; Intellectual property ; International economic relations ; International economics ; International trade ; LDCs ; Negotiation ; Pharmaceuticals ; Property rights</subject><ispartof>Perspectives on global development and technology, 2019-05, Vol.18 (3), p.249-268</ispartof><rights>Copyright 2019 by Koninklijke Brill NV, Leiden, The Netherlands</rights><rights>Copyright Brill Academic Publishers, Inc. May 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,30999,33223,33774</link.rule.ids></links><search><creatorcontrib>Mah, Jai S</creatorcontrib><title>Patents on Pharmaceutical Products in Fair International Economic Relations</title><title>Perspectives on global development and technology</title><description>Abstract Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essential medicines critical to human life and health. The Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) of the WTO includes a few provisions on special and differential treatment (SDT) of developing countries. However, these do not specifically mention pharmaceutical products. Patentability of pharmaceutical products may be analysed in light of fairness. From the viewpoint of distributional fairness, this article derives several policy suggestions for pharmaceutical products in fair international economic relations.</description><subject>Developing countries</subject><subject>Drugs</subject><subject>Fairness</subject><subject>GATT</subject><subject>Intellectual property</subject><subject>International economic relations</subject><subject>International economics</subject><subject>International trade</subject><subject>LDCs</subject><subject>Negotiation</subject><subject>Pharmaceuticals</subject><subject>Property rights</subject><issn>1569-1500</issn><issn>1569-1497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>7UB</sourceid><sourceid>8BJ</sourceid><sourceid>BHHNA</sourceid><recordid>eNp1UMFOAyEQJUYTa_UDvG3ieS2zu1A4mqbVxiY2Rs8EWIg0W6jAHvx7d62NJ08z8968l5mH0C3gewBaz4BQDg2fl1DVDZAKztBkxMoRPD_1BONLdJXSDuMK1xgm6Hkrs_E5FcEX2w8Z91KbPjstu2IbQ9vrgXK-WEkXi7XPJnqZXfADvdTBh73TxavpfrB0jS6s7JK5-a1T9L5avi2eys3L43rxsClVRUkuW8k1GA66sXNSc26p4g1vsbKNYthqqgwlzGhdE2WxgbYdB84IY3POOKmn6O7oe4jhszcpi13oh8O6JKqK8uE1zNmwBcctHUNK0VhxiG4v45cALMbMxCkzccps0MyOGhVd1_3Z_q_4Bi4BbLg</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Mah, Jai S</creator><general>Brill</general><general>Brill Academic Publishers, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7U4</scope><scope>7UB</scope><scope>8BJ</scope><scope>BHHNA</scope><scope>DWI</scope><scope>FQK</scope><scope>JBE</scope><scope>WZK</scope></search><sort><creationdate>20190501</creationdate><title>Patents on Pharmaceutical Products in Fair International Economic Relations</title><author>Mah, Jai S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b265t-da9c1e91c4f75399f6b949d0bf4b80fc6be658ecc35bf0e1dd8ecc98588798953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Developing countries</topic><topic>Drugs</topic><topic>Fairness</topic><topic>GATT</topic><topic>Intellectual property</topic><topic>International economic relations</topic><topic>International economics</topic><topic>International trade</topic><topic>LDCs</topic><topic>Negotiation</topic><topic>Pharmaceuticals</topic><topic>Property rights</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mah, Jai S</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Sociological Abstracts (pre-2017)</collection><collection>Worldwide Political Science Abstracts</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>Sociological Abstracts</collection><collection>Sociological Abstracts</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><collection>Sociological Abstracts (Ovid)</collection><jtitle>Perspectives on global development and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mah, Jai S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patents on Pharmaceutical Products in Fair International Economic Relations</atitle><jtitle>Perspectives on global development and technology</jtitle><date>2019-05-01</date><risdate>2019</risdate><volume>18</volume><issue>3</issue><spage>249</spage><epage>268</epage><pages>249-268</pages><issn>1569-1500</issn><eissn>1569-1497</eissn><abstract>Abstract Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essential medicines critical to human life and health. The Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) of the WTO includes a few provisions on special and differential treatment (SDT) of developing countries. However, these do not specifically mention pharmaceutical products. Patentability of pharmaceutical products may be analysed in light of fairness. From the viewpoint of distributional fairness, this article derives several policy suggestions for pharmaceutical products in fair international economic relations.</abstract><cop>Leiden | Boston</cop><pub>Brill</pub><doi>10.1163/15691497-12341521</doi><tpages>20</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1569-1500
ispartof Perspectives on global development and technology, 2019-05, Vol.18 (3), p.249-268
issn 1569-1500
1569-1497
language eng
recordid cdi_proquest_journals_2269020098
source Applied Social Sciences Index & Abstracts (ASSIA); International Bibliography of the Social Sciences (IBSS); Worldwide Political Science Abstracts; BSC - Ebsco (Business Source Ultimate); Alma/SFX Local Collection; Sociological Abstracts
subjects Developing countries
Drugs
Fairness
GATT
Intellectual property
International economic relations
International economics
International trade
LDCs
Negotiation
Pharmaceuticals
Property rights
title Patents on Pharmaceutical Products in Fair International Economic Relations
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A23%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patents%20on%20Pharmaceutical%20Products%20in%20Fair%20International%20Economic%20Relations&rft.jtitle=Perspectives%20on%20global%20development%20and%20technology&rft.au=Mah,%20Jai%20S&rft.date=2019-05-01&rft.volume=18&rft.issue=3&rft.spage=249&rft.epage=268&rft.pages=249-268&rft.issn=1569-1500&rft.eissn=1569-1497&rft_id=info:doi/10.1163/15691497-12341521&rft_dat=%3Cproquest_cross%3E2269020098%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b265t-da9c1e91c4f75399f6b949d0bf4b80fc6be658ecc35bf0e1dd8ecc98588798953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2269020098&rft_id=info:pmid/&rfr_iscdi=true